Bio View (XTAE:BIOV) PEG Ratio: N/A (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:BIOV Bio View Ltd XTAE:BIOV
41 GF Score
Price ₪0.82
GF Value ₪1.71
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bio View PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Bio View's PE Ratio without NRI is 0.00. Bio View's 5-Year EBITDA growth rate is 0.00%. Therefore, Bio View's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Bio View's PEG Ratio or its related term are showing as below:



XTAE:BIOV's PEG Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.9
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Bio View  (XTAE:BIOV) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Bio View PEG Ratio Related Terms


Bio View PEG Ratio Historical Data

* Premium members only.

The historical data trend for Bio View's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio View PEG Ratio Chart

Bio View Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bio View Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTAE:BIOV vs ABT, SYK, MDT: PEG Ratio Comparison

For the Medical Devices subindustry, Bio View's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio View PEG Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio View's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Bio View's PEG Ratio falls into.


XTAE:BIOV
41GF Score
Bio View Ltd XTAE:BIOV
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio View PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Bio View's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Bio View (XTAE:BIOV) Overvalued in 2026?

Based on GuruFocus' analysis, Bio View stock appears to be undervalued. The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71. GuruFocus considers Bio View to be Possible Value Trap.

Key valuation signals for XTAE:BIOV:

  • PEG Ratio: N/A
  • GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio View Business Description

Address 3 Pekeris Street, Rehovot, ISR, 7670203
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score

Get the complete analysis for XTAE:BIOV

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.82
Price
₪1.71
GF Value